Palivizumab: A review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)

Biologics: Targets and Therapy

Volumn 1, Issue 1, 2007, Pages 33-43

  Geskey, Joseph M ^a   Thomas, Neal J ^a   Brummel, Gretchen L ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Immunoprophylaxis; Monoclonal antibodies; Palivizumab; Pediatrics; Respiratory syncytial virus

Indexed keywords

EID: 70350069949     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Abadesso C, Almeida HI, Virella D, et al. 2004. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit. J Hosp Infect, 58:38-41.
2. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. 2003. Policy statement: revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics, 112:1442-6.
3. Arnold SR, Wang EE, Law BJ, et al. 1999. Variable morbidity of respiratory syncytial virus Infection in patients with underlying lung disease: a review of the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J, 18:866-9.
4. Bala P, Ryan CA, Murphy BP. 2005. Hospital admissions for bronchiolitis in preterm infants in the absence of respiratory syncytial virus prophylaxis. Arch Dis Child Fetal Neonatal Ed, 90:92.
5. Boeckh M, Berrey MM, Bowden RA, et al. 2001. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis, 184:350-4.
6. Boyce TG, Mellen BG, Mitchel EF, et al. 2000. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr, 137:865-70.
7. Broughton S, Roberts A, Fox G, et al. 2005. Prospective study of healthcare utilization and respiratory morbidity due to RSV infection in prematurely born infants. Thorax, 60:1039-44.
8. Carbonell-Estrany X, Quero J, Bustos G, et al. 2000. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: a prospective study. Pediatr Infect Dis J, 19:592-7.
9. Carbonell-Estrany X, Quero J, and the IRIS Study Group. 2001. RSV hospitalization rates in premature infants born over two consecutive seasons. Pediatr Infect Dis J, 20:874-9.
10. Castro C, Arnold JJ, Cameron CE. 2005. Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res, 107:141-9.
11. Chin J, Magoffin RL, Shearer LA, et al. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol, 89:449-63.
12. Cilla G, Sarasua, A, Montes M, et al. 2006. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect, 134:506-13.
13. Clark SJ, Beresford MW, Subhedar NV, et al. 2000. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child, 83:313-6.
14. Cohen A, Sorrentino M, Powers T. 2000. Key findings after a second season of use: effectiveness of palivizumab for preventing serious RSV disease. J Respir Dis Pediatr, 2:S30-2.
15. ® (palivizumab) for prophylaxis of respiratory syncytial virus disease in children with cystic fibrosis [abstract]. American Thoracic Society Abstracts, 2005 International Conference, 2:A178.
16. Committee on Infectious Diseases and Committee on Fetus and Newborn. 2003. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics, 112:1142-6.
17. Community-acquired respiratory viruses. 2004. Am J Transplant, 4(Suppl 10):105-109.
18. Cox RA, Rao P, Brandon-Cox C. 2001. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. J Hosp Infect, 48:186-92.
19. DeVincenzo JP, Aitken J, Harrison L. 2003. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. J Pediatr, 143:123-6.
20. DeVincenzo JP. 2004. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res, 56:914-7.
21. DeVincenzo JP, Hall CB, Kimberlin DW, et al. 2004. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis, 190:975-8.
22. Deshpande SA, Northern V. 2003.The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area. Arch Dis Child, 88:1065-9.
23. Duppenthaler A, Gorgievski-Hrisoho M, Frey U, et al. 2003. Two-year periodicity of respiratory syncytial virus epidemics in Switzerland. Infection, 31:75-80.
24. Duppenthaler A, Ammann RA, Gorgievski-Hrisoho M, et al. 2004. Low incidence of respiratory syncytial virus hospitalizations in haemo-dynamically significant congenital heart disease. Arch Dis Child, 89:961-5.
25. Elhassan NO, Sorbero MES, Hall CB, et al. 2006. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease. Arch Pediatr Adolesc Med, 160:1070-6.
26. Embleton ND, Harkensee C, Mckean MC. 2005. Palivizumab for preterm infants. Is it worth it? Arch Dis Child Fetal Neonatal Ed, 90:286-9.
27. Feltes TF, Cabalka AK, Meissner C, et al. 2003. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr, 143:532-40.
28. Figueras-Aloy J, Carbonell-Estrany X, Quero J, for the IRIS study group. 2004. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J, 23:815-20.
29. Fjaerli HO, Farstad T, Bratlid D. 2004. Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective study.BMC Pediatrics, 4:25.
30. Fulginiti VA, Eller JJ, Sieber OF, et al. 1969. Respiratory virus immunization. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol, 89:435-48.
31. Geskey JM, Ceneviva GD, Brummel G, et al. 2004. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit? Clin Ther, 26: 2130-7.
32. Golombek SG, Berning F, Lagamma EF. 2004. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting. Pediatr Infect Dis J, 23:318-22.
33. Greenough A, Cox S, Alexander J, et al. 2001.Health care utilization of infants with chronic lung disease, related to hospitalization for RSV infection. Arch Dis Child, 85:463-8.
34. Grimaldi M, Gouyon B, Michaut F, et al. 2004. Epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia. Pediatr Infect Dis J, 23:1081-5.
35. Grimaldi M, Gouyon B, Sagot P, et al. 2007. Palivizumab efficacy in preterm infants with gestational age < 30 weeks without bronchopulmonary dysplasia. Pediatr Pulmonol, 42:189-92.
36. Groothuis JR. 2001. Safety and tolerance of palivizumab administration in a large northern hemisphere trial. Pediatr Infect Dis J, 20:628-30.
37. Groothuis JR, Simoes EA, Levin MJ, et al. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med, 329:1524-30.
38. Hall CB, Powell KR, MacDonald NE, et al. 1986. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med, 315:77-81.
39. Hall CB, Walsh EE, Schnabel KC, et al. 1990. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis, 162:1283-90.
40. Hall CB. 2001. Respiratory syncytial virus and parainfluenza virus. N Engl J Med, 344:1917-28.
41. Henckel E, Luthander J, Berggren E, et al. 2004. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Pediatr Infect Dis J, 23:27-31.
42. Heikkinen T, Valkonen H, Lehtonen L, et al. 2005. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Arch Dis Child Fetal Neonatal Ed, 90:F64-8.
43. Henderson J, Hilliard TN, Sherriff A, et al. 2005. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr Allergy Immunoc, 16:386-92.
44. Hiatt PW, Grace SC, Kozinetz CA, et al. 1999. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics, 103:619-26.
45. Hill SR, Mitchell AS, Henry DA. 2000. Problems with interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA, 283:2116-21.
46. Holman RC, Curns AT, Cheek JE, et al. 2004. Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general Unites States infant population. Pediatrics, 114:437-44.
47. Impact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 102:531-7.
48. Iwane MK, Edwards KM, Szilagyi PG, et al. 2004. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics, 113:1758-64.
49. Joffe S, Escobar GJ, Black SB, et al. 1999. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics, 104:894-99.
50. Johnson S, Oliver C, Prince GA, et al. 1997. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis, 176:1215-24.
51. Kamal-Bahl S, Doshi J, Campbell J. 2002. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med, 156:1034-41.
52. Kilani MM, Mohammed KA, Nasreen N, et al. 2004. Respiratory syncytial virus causes increased bronchial epithelial permeability. Chest, 126:186-91.
53. Korppi M, Piippo-Savolainen E, Korhonen K, et al. 2004. Respiratory morbidity 20 years after RSV infection in infancy. Pediatr Pulmonol, 38:155-60.
54. Kusel MMH, de Klerk NH, Holt PG, et al. 2006. Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort study. Pediatr Infect Dis J, 25:680-6.
55. Kusuda S, Koizumi T, Sakai T, et al. 2006. Results of clinical surveillance during the Japanese first palivizumab season in 2002-2003. Pediatr Int, 48:362-8.
56. Lacaze-Masmonteil T, Rozé J-C, Fauroux B, et al. 2002. Incidence of Respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with palivizumab as RSV prophylaxis. Pediatr Pulmonol, 34:181-8.
57. Lacaze-Masmonteil T, Seidenberg J, Mitchell I, et al. 2003. Evaluation of the safety of palivizumab in the second season of exposure in young children at risk for severe respiratory syncytial virus infection. Drug Saf, 26:283-91.
58. Lacaze-Masmonteil T, Truffert P, Pinquier D, et al. 2004. Lower respiratory tract illness and RSV prophylaxis in very premature infants. Arch Dis hild, 89:562-7.
59. Law BJ, Langley JM, Allen U, et al. 2004. The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J, 23:806-14.
60. Leader S, Kohlhase K. 2003. Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr, 143(Suppl): S127-32.
61. Leclair JM, Freeman J, Sullivan BF, et al. 1987. Prevention of nosocomial respiratory syncytial infections through compliance with glove and gown isolation precautions. N Engl J Med, 317:329-34.
62. Liese JG, Grill E, Fischer B, et al. 2003. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr, 162:230-6.
63. Little-van den Hurk SD, Mapletoft JW, Arsic N, et al. 2007. Immunopathology of RSV infection: prospects for developing vaccines without developing this complication. Rev Med Virol, 17:5-34.
64. Macartney KK, Gorelick MH, Manning ML, et al. 2000. Nosocomial respiratory syncytial virus infections: the cost-effectiveness and cost-benefit of infection control. Pediatrics, 106:520-6.
65. McBride SC, Chiang VW, Goldmann DA, et al. 2005. Preventable adverse events in infants hospitalized with bronchiolitis. Pediatrics, 116:603-8.
66. McCormick J, Tubman R. 2002. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr Pulmonol, 34:262-6.
67. McCormick J, Southern KW. 2007. A survey of palivizumab for infants with cystic fibrosis in the UK. Arch Dis Child, 92:87-8.
68. Madge P, Paton JY, McColl JH, et al. 1992. Prospective controlled study of four infection-control procedures to prevent nosocomial infection with respiratory syncytial virus. Lancet, 340:1079-83.
69. Malley R, DeVincenzo J, Ramilo O, et al. 1998. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis, 178:1555-61.
70. Meberg A, Bruu AL. 2006. Respiratory syncytial virus infections in congenital heart defects hospitalizations and costs. Acta Paediatr, 95:404-6.
71. Meissner HC, Long SL, and the Committee on Infectious Diseases and Committee on Fetus and Newborn. 2003. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics, 112:1447-52.
72. Mejías A, Chávez-Bueno S, Ríos AM, et al. 2004. Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother, 48:1811-22.
73. Mejías A, Chávez-Bueno S, Ríos AM, et al. 2005. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother, 49:4700-7.
74. Mitchell I, Tough S, Gillis L, et al. 2006. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Pediatr Pulmonol, 41:1167-74.
75. Mohan AK, Braun MM, Ellenberg S, et al. 2004. Deaths among children less than two years of age receiving palivizumab: an analysis of comorbidities. Pediatr Infect Dis J, 23:342-5.
76. Moore TJ, Weiss SR, Kaplan S, et al. 2002. Reported adverse drug events in infants and children under 2 years of age. Pediatrics, 110:e53.
77. National Center for Health Statistics. 2001. Table 46. Live births, infant deaths, and infant mortality rates by plurality, birthweight, race of mother, and gestational age: United States, 2001 period data [online]. Accessed 2 February 2007. URL: http://www.cdc.gov/nchs/data/dvs/LINK01WK46.pdf
78. Navér L, Eriksson M, Ewald U, et al. 2004. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden. Acta Paediatr, 93:1470-3.
79. Null D, Pollara B, Dennehy PH, et al. 2005. Safety and immunogenicity of palivizumab (Synagis) administered for two seasons. Pediatr Infect Dis J, 24:1021-3.
80. Numa A. 2000. Outcome of respiratory syncytial virus infection and a costbenefit analysis of prophylaxis. J Paediatr Child Health, 36:422-7.
81. Oh PI, Lanctôt KL, Yoon A, et al. 2002. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J, 21:512-8.
82. Ottolini MG, Curtis SR, Mathews A, et al. 2002. Palivizumab is highly effective in suppressing respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant, 29:117-20.
83. Palivizumab Outcomes Registry Study Group. 2003. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from the palivizumab outcomes registry. Pediatr Pulmonol, 35:484-9.
84. Pedraz C, Carbonell-Estrany X, Figueras-Aloy J, et al. 2003. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants. Pediatr Infect Dis J, 22:823-7.
85. Prais D, Danino D, Schonfeld T, et al. 2005. Impact of palivizumab on admission to the ICU for respiratory syncytial virus bronchiolitis: a national survey. Chest, 128:2765-71.
86. Purcell K, Fergie J. 2004. Risk factors, treatment and hospital course in 3308 infants and young children, 1991 to 2002. Pediatr Infect Dis J, 23:418-23.
87. Resch B, Gusenleitner W, Muller WD, Haas J. 2006. Observational study of respiratory syncytial irus-associated hospitalizations and use of palivizumab in premature infants aged 29-32 weeks. Eur J Clin Microbiol Infect Dis, 25:120-2.
88. Robbins JM, Tilford JM, Gillaspy SR, et al. 2002. Parental emotional and time costs predict compliance with respiratory syncytial virus prophylaxis. Ambul Pediatr, 2:444-8.
89. Romero JR. 2003. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998-2002: results from four years of palivizumab usage. Pediatr Infect Dis J, 22:S46-54.
90. Sáez-Lllorens X, Castaño E, Null D, et al. 1998. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J, 17:787-91.
91. Sáez-Llorens X, Moreno MT, Ramilo O, et al. 2004. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus. Pediatr Infect Dis J, 23:707-12.
92. Saji T, Nakazawa M, Harada K. 2005. Safety and efficacy of palivizumab prophylaxis in children with congenital heart disease. Pediatr Int, 47:397-403.
93. Shireman TI, Braman KS. 2002. Impact and cost-effectiveness of RSV prophylaxis for Kansas Medicaid's high-risk children. Arch Pediatr Adolesc Med, 156:1251-5.
94. Sigurs N, Bjarnason R, Sigurbergsson F, et al. 2000. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med, 161:1501-7.
95. Sigurs N, Gustafsson PM, Bjarnason R, et al. 2005. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med, 171:137-41.
96. Simoes EAF, Sondheimer HM, Top FH Jr, et al. Respiratory syncytial virus immuneglobulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr, 133:492-99.
97. Simpson S, Burls A. A systematic review of the effectiveness and costeffectiveness of palivizumab (Synagis) in the prevention of respiratory syncytial virus (RSV) infection infection in infants at high risk of infection. Birmingham UK: Department of Public Health and Epidemiology, University of Birmingham, 2001.Singleton R, Dooley L, Bruden D, et al. 2003. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants. Pediatr Infect Dis J, 22:540-5.
98. Sorrentino M, Powers T, The Palivizumab Outcomes Study Group. 2000. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. Pediatr Infect Dis J, 19:1068-71.
99. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet, 354:541-5.
100. Stevens TP, Sinkin RA, Hall CB, et al. 2000. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier. Arch Pediatr Adolesc Med, 154:55-61.
101. Subcommittee on Diagnosis and Management of Bronchiolitis. 2006. Diagnosis and management of bronchiolitis. Pediatrics, 118:1774-93.
102. Subramanian S, Weisman L, Rhodes T, et al. 1998. Safety, tolerance and pharmacokinetics of humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J, 17:110-5.
103. Swedish Consensus Group. 2001. Management of infections caused by respiratory syncytial virus. Scand J Infect Dis, 33:323-8.
104. Terletskaia-Ladwig, Enders Gisela, Schalasta G, Enders M. 2005. Defining the timing of respiratory syncytial virus (RSV) outbreaks: an epidemiological study. BMC Infect Dis, 5:20.
105. The Impact-RSV Study Group. 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 102:531-7.
106. The PREVENT Study Group. 1997. Reduction of RSV hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics, 99:93-9.
107. Thomas NJ, Hollenbeak CS, Ceneviva GD, et al. 2007. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model. J Pediatr Hematol Oncol, 29:227-32.
108. Thompson WW, Shay DK, Weintraub E, et al. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA, 289:179-86.
109. Vogel AM, Lennon DR, Broadbent R, et al. 2002. Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants. J Paediatr Child Health, 38:550-4.
110. Wang EEL, Law BJ, Stephens D. 1995. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr, 126:212-9.
111. Weigl JAI, Puppe W, Schmitt HJ. 2001. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. Eur J Clin Microbiol Infect Dis, 20:452-9.
112. Willson DF, Landrigan CP, Horn SD, et al. 2003. Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia. J Pediatr, 143:S142-9.
113. Winchester L, García L, García I, Concepción CB. 2002. Prevention of respiratory syncytial virus infection among Puerto Rican infants. P R Health Sci J, 21:191-3.
114. Wolf DG, Greenberg D, Kalkstein D, et al. 2006. Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children. Pediatr Infect Dis J, 25:320-4.
115. Wu SY, Bonaparte J, Pyati S. 2004. Palivizumab use in very premature infants in the neonatal intensive care unit. Pediatrics, 114:e554-6.
116. Yount LE, Mahle WT. 2004. Economic analysis of palivizumab in infants with congenital heart disease. Pediatrics, 114:1606-11.
117. Zhao X, Chen FP, Sullender WM. 2004. Respiratory syncytial virus escapemutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology, 318:608-12.